ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2019
Long-term single-centre large volume experience with transseptal endocardial left ventricular lead implantation.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Percutaneous removal of an inadvertent left-heart implantable cardioverter-defibrillator lead malposition in a nonagenarian: A case report.HeartRhythm case reports · 2026Article
- Recent Advances in Cardiac Resynchronization Therapy: Current Treatment and Future Direction.Journal of clinical medicine · 2025Review
- Article
- The Loop Technique in Cardiac Resynchronization Therapy: A Prospective Cohort Study.International journal of general medicine · 2024Article
- Trans-septal left ventricular endocardial lead in a patient with extensive anterior myocardial infarction and left ventricle (LV) apical endoventriculoplasty using a Vascutek patch-case report.AME case reports · 2024Article
- Phenogrouping and risk stratification of patients undergoing cardiac resynchronization therapy upgrade using topological data analysis.Scientific reports · 2023Article
- A case report of left ventricular lead implantation via total three-dimensional transseptal puncture after tricuspid valve replacement.Frontiers in cardiovascular medicine · 2023Article
- The long-term safety and effectiveness of the loop technique in left ventricular lead dislocation.Frontiers in cardiovascular medicine · 2023Article
- Inadvertent Lead Malposition in the Left Heart during Implantation of Cardiac Electric Devices: A Systematic Review.Journal of cardiovascular development and disease · 2022Review
- Determinants of Response to Cardiac Resynchronization Therapy.The Journal of innovations in cardiac rhythm management · 2022Article
- Concomitant Transatrial and Transapical CRT-D Lead Implantation in a Patient with Chest Burn Injury.The Thoracic and cardiovascular surgeon reports · 2022Article
- Cardiac resynchronization therapy with intraoperative epicardial mapping via minithoracotomy: 10 years' experience.Pacing and clinical electrophysiology : PACE · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of our study was to investigate the long-term efficacy and safety of transseptal endocardial left ventricular lead implantation (TELVLI). METHODS AND
resultsTransseptal endocardial left ventricular lead implantation was performed in 54 patients (44 men, median age 69, New York Heart Association III-IV stage) between 2007 and 2017 in a single centre. In 36 cases, the transseptal puncture (TP) was performed via the femoral vein, and in 18 cases, the TP and also the left ventricular (LV) lead placement were performed via the subclavian vein. An electrophysiological deflectable catheter was used to reach the LV wall through the dilated TP hole. The LV lead implantation was successful in all patients. A total of 54 patients were followed up for a median of 29 months [interquartile range (IQR) 8-40 months], the maximum follow-up time was 94 months. Significant improvement in the LV ejection fraction was observed at the 3-month visit, from the median of 27% (IQR 25-34%) to 33% (IQR 32-44%), P < 0.05. Early lead dislocation was observed in three cases (5%), reposition was performed using the original puncture site in all. The patients were maintained on anticoagulation therapy with a target international normalized ratio between 2.5 and 3.5. Four thromboembolic events were noticed during follow-up. A total of 27 patients died, with a median survival of 15 months (IQR 6-40).
conclusionThe TELVLI is an effective approach for cardiac resynchronization therapy (CRT) however it is associated with a substantial thromboembolic risk (7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.